BioAtla (BCAB) Stock: Buy, Sell, or Hold?
BCAB - BioAtla, Inc. Common Stock
$1.74
-1.41 (-44.75%)
▼
5d:
-45.44%
30d:
-48.67%
90d:
-55.85%
WAIT
LOW Confidence
Analysis Updated: Aug 28, 2026 12:00 AM ET
Earnings: Aug 06, 2026
0d
Get Alerted When BCAB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: BCAB is down 45.4% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: BCAB is down 45.4% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: BCAB is currently trading at $1.74, which is considered fair based on recent price action.
Technical Outlook: Technically, BCAB is in a downtrend. Immediate support is located at $1.51, while resistance sits at $4.00. Short-term momentum is weak, with the stock down 44.7% recently.
Market Sentiment: BCAB scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $10.00 (+476.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, BCAB is in a downtrend. Immediate support is located at $1.51, while resistance sits at $4.00. Short-term momentum is weak, with the stock down 44.7% recently.
Market Sentiment: BCAB scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $10.00 (+476.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Company Quality Score
39/100
(SELL)
Volume Confirmation
UNKNOWN
Confidence Score
39.5%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (25/100)
- BEARISH: Downward momentum (-44.7%)
- BULLISH: Trading 476.4% below Wall St target ($10.00)
- WARNING: Composite score 39/100 in the bottom quintile — this cohort historically lags the market
Support & Resistance Levels
Support Level
$1.51
Resistance Level
$4.00
Current Trend
Downtrend
Technical data as of
Aug 28, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.30
Wall Street Target
$10.00
(+476.4%)
Revenue Growth (YoY)
31.6%
Share & Embed Analysis
Last updated: October 22, 2026 9:32 AM ET
Data refreshes hourly during market hours. Next update: 10:32 AM
Data refreshes hourly during market hours. Next update: 10:32 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BCAB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ARGX
argenx NV ADR |
STRONG BUY
25 analysts |
$1153 | 58 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
24 analysts |
$139 | 54 HOLD |
|
IRD
Opus Genetics, Inc. |
STRONG BUY
18 analysts |
$13 | 58 HOLD |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
17 analysts |
$141 | 59 HOLD |
|
CLYM
Climb Bio Inc |
STRONG BUY
15 analysts |
$28 | 67 BUY |
